May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Kentucky's New Governor Could Change the Terms of Medicaid Expansion
Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents
Ted Okon Outlines the Purpose of COA's Payer Exchange Summit